Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2025
0mins
Should l Buy ?
Source: Newsfilter
Presentation of Phase 2a Trial Data: Lipella Pharmaceuticals will present topline data from its Phase 2a trial of LP-310, a liposomal tacrolimus oral rinse for Oral Lichen Planus, on May 15, 2025, showing significant safety and efficacy results from the 0.50 mg dose cohort.
Positive Treatment Outcomes: The treatment demonstrated statistically significant improvements in pain and inflammation, with no serious adverse events reported, indicating LP-310's potential as a localized, non-steroidal therapy for Oral Lichen Planus.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
